



2018 Research Roundtable for Epilepsy
Evolving concepts in endpoints and populations
in epilepsy trials

May 17-18, 2018
American Institute of Architects
Washington, DC

Day One: Thursday, May 17, 2018

12:00 PM **Registration and lunch** (*AIA, Social Gallery outside Boardroom*)

1:00 PM **Welcome** (*Dr. Brandy Fureman and Mr. Phil Gattone*)

Meeting goals and deliverables (*Dr. Nathan Fountain and Dr. Jacqueline French*)

1:10 PM **Session I: Perspectives on past and current RRE**

1:10pm Overview of 2017 RRE discussion (*Drs. French and Fountain*)

1:30pm Interval developments & Potential next steps
(*Dr. O'Neill D'Cruz*)

1:50pm Perspective on the approval of devices for seizures (*Dr. William Heetderks*)

2:00pm European regulatory perspective (*Dr. Sylvie Benchetrit – via webinar*)

2:10pm Where we've been and where we're going (*Dr. Billy Dunn*)

2:20pm Discussion

2:40 PM **Break**

3:00 PM **Session II: Considerations for grouping vs. splitting**

3:00pm Introduction: Why do we group now? What are alternatives? Grouping by seizure type, by syndrome or by etiology - and how this influences interventions (*Dr. Nathan Fountain*)



- 3:15pm Define anti-ictal and anti-mechanistic/mechanism-targeted (*Dr. Michael Rogawski*)
- 3:30pm Historical perspective on epilepsy drug development (*Dr. Lynn Kramer*)
- 3:45pm Lennox-Gastaut: What we know (*Dr. Dennis Dlugos*)
- 4:00pm Are drop attacks or seizure types found in multiple rare syndromes orphan? (*Dr. Allen Hauser*)
- 4:15pm Paradigm in clinical trials for studying seizures rather than syndromes, and why it makes sense (*Dr. Jacqueline French*)
- Proposal: drugs that are thought to be mechanistically anti-ictal should be studied in the seizure types (regardless of syndrome), and drugs that work on the disease mechanism can be studied in the syndrome or etiology*
- 4:30pm Open discussion & Proposal resolution
- 5:20 PM Wrap up & End of Day One**
- 6:00 PM Reception** (*W Hotel, Altitude Foyer and POV Terrace*)
- 7:00 PM Dinner** (*W Hotel, Altitude Restaurant*)



2018 Research Roundtable for Epilepsy
Evolving concepts in endpoints and populations
in epilepsy trials

Day Two: Friday, May 18, 2018

8:00 AM **Breakfast** (*AIA Social Gallery*)

9:00 AM **Meeting start** (*AIA Boardroom*)

9:05 AM **Session III: The full spectrum of the disease: Treatment and outcome assessment in epileptic conditions that comprise more than seizures**

9:05am Parent/advocate panel
(Tuberous Sclerosis Alliance: Dr. Steven Roberds; Lennox-Gastaut Syndrome Foundation: Dr. Tracy Dixon Salazar; Dravet Syndrome Foundation: Ms. Mary Anne Meskis)

9:25am What is the full spectrum of the disease? Comorbidities data from the Rare Epilepsy Network *(Dr. Brandy Fureman)*

9:45am How are comorbidities associated with epilepsy? When would you expect treatment of the epilepsy to also treat the comorbidities, or how would you expect treatment to impact the comorbidities? How would you differentiate acute effects of treatment on comorbidities versus disease modifying effects?
(Dr. Ingrid Scheffer)

10:05am Combined outcomes in conditions where seizures and comorbidities have a shared mechanism, example Tuberous Sclerosis *(Dr. Steven Roberds)*

10:20am Combined outcome in epileptic encephalopathies where the mechanism is not completely understood, eg. Lennox-Gastaut Syndrome *(Dr. Tracy Dixon Salazar)*

10:35am Discussion

Framework - Understanding of what are the most important comorbidities in each of the syndromes that are of interest to study. Are the comorbidities directly related to the mechanism of the seizure or the mechanism of the drug and therefore within the scope of what should be studied in the trial? Or are the comorbidities outside of the scope of what you could look to change in a trial?

11:35 AM **Break**



11:50 AM Session IV: Measurements outside of seizure

- 11:50am Methodology and practical applications for incorporating cognitive and QOL outcome measures in epilepsy-related syndromes (*Dr. Madison Berl*)
- 12:05pm Discussion (*Additional discussant: Dr. Maureen Neary*)
- 12:25pm New methodology for assessing totality of epilepsy-related syndromes (*Dr. Rima Nabbout*)

12:45 PM Lunch

1:40 PM Session IV, Cont'd

- 1:45pm Statistical considerations for trial designs with multiple outcomes (*Dr. Jordan Elm*)
- Alternative strategies for:*
- 1) *Looking at multiple symptoms of a disease in an integrated way*
 - 2) *looking at multiple symptoms of a disease in a hierarchical fashion that takes into consideration type one error, etc.*
- 2:05pm Assessment of cognition in children with developmental delay (*Dr. Maureen Neary*)
- 2:20pm Panel introduction (*Dr. Erika Augustine*)
- 2:25pm Trials with multiple outcomes: Member company representatives panel (*Panelists: Dr. Christopher Missling, Anavex; Dr. Lloyd Knapp, Pfizer; Mr. Louis Ferrari, SK Life Science; Dr. Stefan Schwabe, Supernus; Dr. Deborah Lee, Takeda; Dr. Gail Farfel, Zogenix*)
- How would we capture non-epilepsy symptoms in orphan syndromes?*
- 1) *Differentiate optimal disease or syndrome types where this is applicable*
 - 2) *Principles for operationalizing: How to design questionnaire, how to test it and how to implement it*
- 2:35pm Discussion: Specific recommendations of how to implement measurement of other domains (*Additional discussant: Dr. Erika Augustine*)

3:25 PM Discussion and Conclusions

4:10 PM Adjourn